How would gathering preclinical data and improving research infrastructure facilitate clearer definitions of “population vulnerability” and “risk acceptability”?
AMA J Ethics. 2020;22(1):E43-49. doi:
10.1001/amajethics.2020.43.
Clara C. Hildebrandt, MD and Jonathan M. Marron, MD, MPH
Gene editing with CRISPR/Cas9 raises concerns about equitable access to therapies that could limit research participation by minority group members. These concerns can be addressed through public education, transparency, and stakeholder partnerships.
AMA J Ethics. 2018;20(9):E826-833. doi:
10.1001/amajethics.2018.826.
Cyrus Ahalt, MPP, Rebecca Sudore, MD, Marielle Bolano, Lia Metzger, Anna M. Darby, MD, MPH, and Brie Williams, MD, MS
The teach-to-goal method should be used to assess comprehension of incarcerated patients and other vulnerable groups during the informed consent process.
AMA J Ethics. 2017;19(9):862-872. doi:
10.1001/journalofethics.2017.19.9.peer3-1709.
LaPrincess C. Brewer, MD, MPH and Lisa A. Cooper, MD, MPH
Stressful life experience associated with racial and ethnic discrimination can have detrimental effects on the coronary and cardiovascular health of people in historically marginalized groups.
Christina Krudy, MD and Kavita Shah Arora, MD, MBE
Antenatal corticosteroids aren’t as effective in reducing neonatal mortality in low-income as high-income regions due to cultural and health care differences.
AMA J Ethics. 2018;20(3):261-268. doi:
10.1001/journalofethics.2018.20.3.stas1-1803.